1. Home
  2. BANX vs MDWD Comparison

BANX vs MDWD Comparison

Compare BANX & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BANX

ArrowMark Financial Corp.

N/A

Current Price

$21.00

Market Cap

201.5M

Sector

Finance

ML Signal

N/A

Logo MediWound Ltd.

MDWD

MediWound Ltd.

N/A

Current Price

$13.47

Market Cap

181.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BANX
MDWD
Founded
N/A
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
201.5M
181.1M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
BANX
MDWD
Price
$21.00
$13.47
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
36.7K
110.9K
Earning Date
01-01-0001
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$48.92
Revenue Next Year
N/A
$35.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.45
$12.52
52 Week High
$23.67
$20.03

Technical Indicators

Market Signals
Indicator
BANX
MDWD
Relative Strength Index (RSI) 61.38 46.58
Support Level $21.01 $12.52
Resistance Level $21.29 $15.08
Average True Range (ATR) 0.26 0.57
MACD -0.00 0.09
Stochastic Oscillator 75.53 43.23

Price Performance

Historical Comparison
BANX
MDWD

About BANX ArrowMark Financial Corp.

ArrowMark Financial Corp is a non-diversified, closed-end management investment company. The Fund's objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: